PURPOSE: To evaluate the long-term efficacy of ranibizumab in the treatment of @entity2479 ( @entity2479 ) and to identify predictors of functional outcome. METHODS: Retrospective case series comprised 79 eyes of 68 consecutive @entity1 with @entity2479 followed up >= 36 months. Primary end-points were best-corrected visual acuity (BCVA) and @entity1020 ( @entity1020 ) variation at 36 months and at the last visit. RESULTS: Mean follow-up time was 59.8    16.0 months. All eyes were treated with pro re nata ranibizumab, with (n = 33) or without (n = 46) photodynamic therapy (PDT). Stabilization or improvement in BCVA was observed in 50.6% of the @entity1 at 36 months, and in 40.5% at the end of the follow-up, where 20.3% preserved reading vision. A significant decrease in @entity1020 was observed at 36 months (p < 0.001), but not at the end of the follow-up. @entity10691 ( @entity10691 ) was present in 59.5% of the eyes at the final visit. Baseline subretinal fluid was associated with better visual outcomes (p = 0.001). Results of combination treatment with intravitreal ranibizumab and PDT did not significantly differ from ranibizumab monotherapy. CONCLUSION: Modest functional outcomes can be expected from the long-term treatment of @entity989 in clinical practice, most likely due to the advent of @entity10691 . Baseline subretinal fluid positively correlated with final BCVA.

Long-Term Management of XXXX Lesions in Clinical Practice: Treatment Efficacy and Predictors of Functional Improvement.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10691 :: ('MESH:D057092', 'Disease') :: ['Geographic atrophy', 'GA'] @entity2479 :: ('MESH:D012173', 'Disease') :: ['retinal angiomatous proliferation', 'RAP'] @entity989 :: ('MESH:D012164', 'Disease') :: ['RAP lesions'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness']
@entity2479 :: (MESH:D012173,Disease) :: ['RAP']
